Literature DB >> 22717785

Changes in urinary nerve growth factor and prostaglandin E2 in women with overactive bladder after anticholinergics.

Kang Jun Cho1, Hyo Sin Kim, Jun Sung Koh, Joon Chul Kim.   

Abstract

INTRODUCTION AND HYPOTHESIS: The aim of this study is to investigate changes in urinary nerve growth factor (NGF) and prostaglandin E(2) (PGE(2)) in women with overactive bladder (OAB) following anticholinergic treatment.
METHODS: A total of 30 female patients with OAB were enrolled and the control group included 15 healthy women who did not present any bladder symptoms. All subjects with OAB recorded voiding diaries, underwent urodynamic study, and were evaluated for urgency grade. They received anticholinergic treatment for 4 weeks, after which they were again evaluated for urinary urgency grade and voiding diaries. OAB patients were classified into three groups according to the change on the 5-point Urinary Sensation Scale after the treatment: group 1 (no change in urgency grade), group 2 (1 point of improvement), and, group 3 (more than 2 points of improvement). Urinary NGF and PGE(2) levels between controls and OAB patients (before and after treatment in groups 1, 2, and 3) were compared.
RESULTS: Urinary NGF and PGE(2) levels were significantly higher in OAB patients than in the controls. NGF levels were not significantly different between pre- and post-treatment in groups 1 and 2. However, in group 3, NGF levels were significantly decreased after treatment. PGE(2) levels were not significantly different between pre- and post-treatment in either group.
CONCLUSIONS: NGF and PGE(2) have important roles in the development of OAB symptoms in women. Initial reduction of urgency severity after anticholinergic treatment in women with OAB could be associated with decreasing urinary NGF levels.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22717785     DOI: 10.1007/s00192-012-1854-4

Source DB:  PubMed          Journal:  Int Urogynecol J        ISSN: 0937-3462            Impact factor:   2.894


  28 in total

1.  Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom.

Authors:  Joon Chul Kim; Eun Young Park; Sung Hoo Hong; Seong Il Seo; Yong Hyun Park; Tae-Kon Hwang
Journal:  Int J Urol       Date:  2005-10       Impact factor: 3.369

2.  Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study.

Authors:  Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams
Journal:  Eur Urol       Date:  2006-10-02       Impact factor: 20.096

Review 3.  Bladder activation: afferent mechanisms.

Authors:  Karl-Erik Andersson
Journal:  Urology       Date:  2002-05       Impact factor: 2.649

4.  Clinical and experimental studies on the action of prostaglandins and their synthesis inhibitors on detrusor muscle in vitro and in vivo.

Authors:  M I Bultitude; N H Hills; K E Shuttleworth
Journal:  Br J Urol       Date:  1976

5.  Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder.

Authors:  Joon Chul Kim; Eun Young Park; Seong Il Seo; Yong Hyun Park; Tae-Kon Hwang
Journal:  J Urol       Date:  2006-05       Impact factor: 7.450

6.  Prostaglandin facilitates afferent nerve activity via EP1 receptors during urinary bladder inflammation in rats.

Authors:  Makoto Ikeda; Masahito Kawatani; Takayuki Maruyama; Hiroko Ishihama
Journal:  Biomed Res       Date:  2006-04       Impact factor: 1.203

7.  Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity.

Authors:  Victor W Nitti; Eric S Rovner; Tamara Bavendam
Journal:  BJU Int       Date:  2009-11-04       Impact factor: 5.588

8.  Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice.

Authors:  Annette Schröder; Donald Newgreen; Karl-Erik Andersson
Journal:  J Urol       Date:  2004-09       Impact factor: 7.450

9.  Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function.

Authors:  W D Steers; S Kolbeck; D Creedon; J B Tuttle
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

10.  Prevalence and burden of overactive bladder in the United States.

Authors:  W F Stewart; J B Van Rooyen; G W Cundiff; P Abrams; A R Herzog; R Corey; T L Hunt; A J Wein
Journal:  World J Urol       Date:  2002-11-15       Impact factor: 4.226

View more
  11 in total

1.  Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery.

Authors:  Sheng-Fu Chen; Yuan-Hong Jiang; Hann-Chorng Kuo
Journal:  Int Urol Nephrol       Date:  2017-08-02       Impact factor: 2.370

2.  Stimulation of the pelvic nerve increases bladder capacity in the prostaglandin E2 rat model of overactive bladder.

Authors:  Christopher L Langdale; James A Hokanson; Arun Sridhar; Warren M Grill
Journal:  Am J Physiol Renal Physiol       Date:  2017-06-14

3.  Changes in nerve growth factor level and symptom severity following antibiotic treatment for refractory overactive bladder.

Authors:  G Vijaya; R Cartwright; A Derpapas; P Gallo; R Fernando; V Khullar
Journal:  Int Urogynecol J       Date:  2013-02-02       Impact factor: 2.894

Review 4.  Management of refractory OAB in the non-neurogenic patient.

Authors:  Bassem S Wadie
Journal:  Curr Urol Rep       Date:  2014-09       Impact factor: 3.092

5.  Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?

Authors:  Axel Hegele; Sonja Knippschild; Carsten Frohme; Jörg Hänze; Peter Olbert; Rainer Hofmann
Journal:  BMC Urol       Date:  2014-11-04       Impact factor: 2.264

6.  Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate.

Authors:  Yoon Seok Suh; Kwang Jin Ko; Tae Heon Kim; Hyo Serk Lee; Hyun Hwan Sung; Won Jin Cho; Munjae Lee; Kyu-Sung Lee
Journal:  Int Neurourol J       Date:  2017-09-12       Impact factor: 2.835

Review 7.  Partners in Crime: NGF and BDNF in Visceral Dysfunction.

Authors:  Ana Coelho; Raquel Oliveira; Tiago Antunes-Lopes; Célia Duarte Cruz
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

Review 8.  The use of urinary biomarkers in the diagnosis of overactive bladder in female patients. A systematic review and meta-analysis.

Authors:  Sofia Tsiapakidou; Apostolos Apostolidis; Konstantinos Pantazis; Grigoris F Grimbizis; Themistoklis Mikos
Journal:  Int Urogynecol J       Date:  2021-08-07       Impact factor: 2.894

9.  Characteristics of the Urinary Proteome in Women with Overactive Bladder Syndrome: A Case-Control Study.

Authors:  Marianne Koch; Pavel Lyatoshinsky; Goran Mitulovic; Barbara Bodner-Adler; Sören Lange; Engelbert Hanzal; Wolfgang Umek
Journal:  J Clin Med       Date:  2021-05-31       Impact factor: 4.241

Review 10.  Rationale for the use of prostaglandins and phosphodiesterase inhibitors in the treatment of functional bladder disorders.

Authors:  Mohammad Sajjad Rahnama'i; Gommert A Van Koeveringe; Philip E Van Kerrebroeck
Journal:  Nephrourol Mon       Date:  2013-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.